Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen’s Stealth Enbrel Patent May Block Biosimilars; Scenario May Apply To Other Biologics

Executive Summary

Amgen’s patent may keep Enbrel biosimilars off the market until at least 2028. Other biosimilar sponsors could face similar submarine patents that derail their commercialization plans.


Related Content

Sandoz Skips Enbrel Biosimilar Patent Dance, Spurs Infringement Suit
Sandoz’s Enbrel Biosimilar Filing May Spur New Litigation
Merck’s Revised Biosimilar Strategy Poised To Deliver
Sandoz Still Trying To Sneak Past Amgen’s Stealth Enbrel Patents
After The Anti-TNFs, What’s Next In Autoimmune Disease?
Sandoz Biosimilar Strategy For Etanercept: Start Small, But Test Globally
And Now For The Real Biosimilar Opportunity: Antibodies And Complex Biologics
Merck Lands Late-Stage Enbrel Biosimilar In Deal With South Korea's Hanwha
Will A Dividend Keep Investors Happy As Amgen Waits For Its Pipeline To Pan Out?
The Cabilly Saga: New Patent, New Product, New Lawsuits


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts